Skip to main content

Elidel Disease Interactions

There are 2 disease interactions with Elidel (pimecrolimus topical).

Major

Topical calcineurin inhibitors (applies to Elidel) immunosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

The use of calcineurin inhibitors as pimecrolimus and tacrolimus topical should be avoided in immunocompromised adults and children, including patients on systemic immunosuppressive medications. Although causal relationship has not been established, there is a concern about a potential risk of infections, lymphomas and skin malignancies when using topical calcineurin inhibitors for a prolonged time.

References

  1. (2001) "Product Information. Protopic (tacrolimus topical)." Fujisawa
  2. (2002) "Product Information. Elidel (pimecrolimus topical)." Novartis Pharmaceuticals
Moderate

Topical calcineurin inhibitors (applies to Elidel) skin malignancies

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Skin Cancer

The use of calcineurin inhibitors such as pimecrolimus and tacrolimus topical should be avoided on malignant or premalignant skin conditions. Some of these conditions might present as dermatitis. Calcineurin inhibitors should also be avoided in any skin conditions where there is the potential for increased systemic absorption of the medication as when there is a skin barrier defect.

References

  1. (2001) "Product Information. Protopic (tacrolimus topical)." Fujisawa
  2. (2002) "Product Information. Elidel (pimecrolimus topical)." Novartis Pharmaceuticals

Elidel drug interactions

There are 92 drug interactions with Elidel (pimecrolimus topical).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer